Hepatic veno-occlusive disease (VOD) is one of the most serious complications in patients receiving stem cell transplantation (SCT). However, the cause of VOD remained to be elucidated. Vascular endothelial growth factor (VEGF) has been reported to have various physiological effects including neovascularization and acceleration of vasopermeability. Because we postulated that VEGF could be one of the causative factors in VOD after SCT, serum VEGF levels were measured by ELISA in 50 patients receiving SCT. Six of the patients showed typical manifestations of VOD and four of them died due to VOD. The mean maximum serum VEGF level in the six patients with VOD was markedly increased compared to that in the patients without VOD (P Ͻ 0.001) and in normal controls (P Ͻ 0.001). Moreover, the mean maximum serum VEGF level in patients with VOD before conditioning chemoradiotherapy for SCT was also high compared to patients without VOD (P = 0.0012) in the same period. Similarly, serum VEGF levels were significantly higher in patients whose plasma protein C activities decreased below 40% (P Ͻ 0.001). During the clinical course of VOD after SCT, the increase of serum VEGF synchronized fairly well with the development of VOD. Since VEGF causes the expression of tissue factor on circulating monocyte/ macrophages and results in hypercoagulability, our observation suggests that in the patients with VOD who showed high serum VEGF it might account for the development of VOD. Furthermore, this observation may indicate a novel therapeutic strategy for prevention of VOD. Bone Marrow Transplantation (2001) 27, 1173-1180.
Stem cell transplantation (SCT) is an effective treatment for hematological diseases and inborn errors of metabolism. Hepatic veno-occulusive disease (VOD), however, is considered to be one of the most significant complications. VOD is clinically diagnosed when at least two of the three following features appear within 30 days after SCT: (1) jaundice, (2) development of hepatomegaly and/or right upper quadrant pain, and (3) ascites and/or unexplained weight gain. 1, 2 Since the prognosis of patients with VOD is extremely poor and effective treatment for VOD has not yet been established, the forecasting of VOD and the identification of its causative agents are urgently needed. Although coagulation abnormalities [3] [4] [5] involving protein C and several cytokines [6] [7] [8] such as tumor necrosis factor-alpha and the others have been considered as possible causative agents of VOD, the etiology of VOD remains unclear.
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), has been cloned and reported to have various physiological effects including neovascularisation and acceleration of vasopermeability. [9] [10] [11] [12] [13] Based on the similarity between the diverse effects of VEGF and the clinical characteristics of VOD such as ascites, hepatomegaly, and acceleration of vasopermeability, we postulated that VEGF might be one of causative factors in VOD after SCT. Moreover, the analysis of VEGF during SCT as a possible causative agent for VOD has not been previously reported. Therefore, we measured the serum VEGF concentration in patients receiving SCT, and evaluated the risk factors for VOD, including plasma protein C, relating to serum VEGF before and after transplantation.
Patients and methods

Subjects
Between April 1996 and March 2000, a total of 50 children (32 males and 18 females) received SCT: 23 patients from HLA-identical related donors, 18 from HLA-identical unrelated donors, and nine with autologous marrow or peripheral blood stem cells. All of these patients were included in this study. Informed consent was obtained from each of Bone Marrow Transplantation their parents. The patients' mean age was 8.3 years (range, 1-21). Indications for transplantation were: acute lymphoblastic leukemia in 12 patients, aplastic anemia in eight, acute myelogenous leukemia in eight, myelodysplastic syndrome in five, non-Hodgkin's lymphoma in four, neuroblastoma in three, rhabdomyosarcoma in two, Wiscott-Aldrich syndrome in two, and chronic myelogenous leukemia, juvenile chronic myelogenous leukemia, fibrosarcoma, hepatoblastoma, yolk sac tumor, and Hunter syndrome in one each.
Twenty age-and sex-matched children were studied as controls. These children had been admitted for selective surgeries such as inguinal herniation, or were undergoing investigation for suspected endocrinological diseases. All of the control subjects were afebrile, free of medication, and otherwise healthy. Informed consent was obtained from each of their parents.
Serum and plasma samples were obtained from patients before conditioning therapy, on days 0, +7, +14, +21 and +30. All samples were centrifuged at 2000 r.p.m. for 15 min, and stored at −80°C until used.
Conditioning regimen and graft-versus-host disease (GVHD) prophylaxis
The conditioning regimen consisted of cyclophosphamide (CY) or melphalan (L-PAM), etoposide (VP-16) or Ara-C, and total body irradiation (TBI) in 24 patients. Busulfan (BU), and CY or L-PAM with or without VP-16 were administered in 14 patients. The remaining patients were conditioned as follows: total lymphoid irradiation and CY in four patients; CY only in two patients, carboplatin; VP-16, and L-PAM in five patients. Both BU and TBI were administered in one patient.
Seventeen patients received prophylaxis against GVHD with antithymocyte globulin (ATG). Thirty-two patients received prophylaxis against GVHD with cyclosporin A (CsA) or tacrolimus (FK506) in combination with MTX according to the Seattle schedule.
14 Six patients received CsA with methlprednisolone. One patient received CsA alone, and two patients received MTX alone.
VOD prophylaxis, diagnosis and treatment
All of the patients received continuous infusions of low molecular weight heparin, 100 unit/kg/day as prophylaxis against VOD from day −7 to day +30. VOD was diagnosed and graded according to McDonald's criteria.
1,2 Treatment of VOD was carried out with supportive care such as platelet, fresh frozen plasma, antithrombin-III transfusions, diuretics, dialysis, and so on. One patient, case 1, received tissue plasminogen activator 3 ϫ 10 5 unit/kg/day for 3 days.
Supportive care
Antibacterial and antifungal prophylaxis was administered with oral polymixin B and amphotericin B, inhaled vancomycin, tobracin and amphotericin B. Antiviral prophylaxis was administered with oral acyclovir from day −7 to day +35 and weekly intravenous anti-cytomegalovirus (CMV) high titer ␥-globulin from day -6 to day +90. Granulocyte colony-stimulating factor (G-CSF) was given intravenously at 5 g/kg from day +5 to engraftment, defined as an absolute neutrophil count of 500/l for 3 consecutive days. Oral mucositis was treated with intravenous pentazocine and parental nutrition.
Acute GVHD was diagnosed and graded according to the Seattle criteria. 15 Treatment of acute GVHD was with prednisolone, methylprednisolone, CsA and/or FK506. CMV infection was diagnosed in the presence of positive CMV antigenemia. Treatment of CMV infection was with ganciclovir and anti-CMV high titer ␥-globulin.
Quantification of VEGF and protein C
Serum VEGF levels were measured in duplicate by a sensitive and highly specific colorimetric ELISA, as previously described. 16, 17 Plasma protein C activities were measured using Testzym Protein C (Daiichi-kagaku, Tokyo, Japan), according to the manufacturer's protocol. This is a photometric assay that uses Protac as an activator of protein C. The amount of activated protein C is determined by the rate of hydrolysis of the chromogenic substrate S-2366. The hydrolysate, p-nitroaniline, release measured at 405 nm is proportional to the protein C activities of normal plasma. The reference range is 82-112%.
Statistical analysis
Statistical analyses were completed using the MannWhitney U test for unpaired samples, the Wilcoxon signedrank test for paired samples, the chi-square test for independence, and Fisher's exact probability test. Each test was performed with a 5% level of significance.
Results
Among 50 patients, six patients (12.0%) developed VOD. Two of them had ALL, and the others had rhabdomyosarcoma, myelodysplastic syndrome (MDS), AML, and nonHodgkin's lymphoma (NHL), respectively. Two patients had moderate forms of VOD, and the rest all had severe forms of VOD. In all these six patients, VOD occurred on days +6 to +10, concomitant with their hematological recovery ( Table 1) . The clinical episodes, changes in plasma protein C activities and serum VEGF levels of the six patients with VOD during the course of SCT are shown in Figure 1 . As shown in Table 2 , the mean serum maximum VEGF level in patients with VOD (772.1 (s.d. 1213.9) pg/ml) was high compared to that in patients without VOD (12.7 (s.d. 42.6) pg/ml; P Ͻ 0.001) and normal controls (52.6 (s.d. 14.8) pg/ml; P Ͻ 0.001). There were no significant correlations between VOD and age, sex, disease, radiation or BU in the conditioning regimen, remission stage, source of stem cells, and severity of acute GVHD. However, the maximum CRP level (P = 0.0046), and the febrile episodes after transplantation (P = 0.0019) were significantly higher in patients with VOD than non-VOD patients (Table 2) . Moreover, the maximum serum VEGF BU = busulfan; VP-16 = etoposide; CY = cyclophosphamide; L-PAM = melphalan; GVHD = graft-versus-host disease; ATG = antithymocyte globulin; TBI = total body irradiation; VOD = hepatic veno-occlusive disease; ALL = acute lymphoblastic leukemia; RMS = rhabdomyosarcoma; MDS = myelodysplastic syndrome; AML = acute myelogenous leukemia; NHL = non-Hodgkin's lymphoma.
level in patients with VOD before SCT (89.1 (s.d. 58.7) pg/ml) was also higher than that in patients without VOD before SCT (22.4 (s.d. 36.4) pg/ml; P = 0.0012, Table 2 ). The increase of serum VEGF levels synchronized fairly well with the development of VOD ( Figure 1 ). Thus, despite a small-scale analysis, serum VEGF level may be used as a parameter not only for diagnosis of VOD after SCT but also for predicting VOD before SCT. Plasma protein C activities showed no differences between patients with VOD and without VOD before transplantation (data not shown). However, the minimum plasma protein C activities in patients with VOD after SCT (22.5% (s.d. 5.3)) were significantly lower than those in the patients without VOD in the same period (49.5% (s.d. 17.0); P Ͻ 0.001) ( Table 2 ). It was found that the reduction of plasma protein C activities below 40% after SCT was seen exclusively in patients with VOD, but not in those without VOD (Table 3) . Therefore, we were convinced that a 40% or higher reduction of plasma protein C after SCT was a significant risk factor for VOD. Then, we analyzed the risk factors for the depression of plasma protein C below 40%. Age, sex, disease, radiation or BU in conditioning regimen, remission stage, source of stem cells, and severity of acute GVHD were not significant risk factors. In contrast, the maximum serum VEGF levels before (P = 0.0016) and after SCT (P Ͻ 0.001), the maximum CRP levels (P = 0.0057), and the febrile terms after transplantation (P = 0.001) were found to be significant risk factors for the depression of plasma protein C (Table 3) .
In this study, the serum transaminase levels were within the normal range in all patients before transplantation. Hepatitis B surface antigen, hepatitis C antibody, and CMV antigenemia were also negative in patients with VOD before and after SCT. Moreover, acute GVHD in patients with VOD was diagnosed and graded zero, although jaundice due to VOD was present. Furthermore, the increase of VEGF and the decrease of protein C were not present in patients with acute/chronic GVHD and CMV infection (data not shown). Thus, in the patients with VOD, it was considered that there was no inflammatory process due to GVHD and/or some viral hepatitis, and both VEGF and protein C levels might be special parameters of VOD, but not GVHD and viral hepatitis.
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Discussion
In this study, we firstly showed that the mean maximum serum VEGF level in patients with VOD after SCT was significantly higher than that in patients without VOD, and the increase of VEGF during the course of SCT synchronized well with the clinical severity of VOD. Moreover, the serum VEGF levels before SCT were significantly higher in patients with VOD than those without VOD. Based on these results, we conclude that the serum VEGF level is not merely a diagnostic parameter for VOD, but also a predicting factor for VOD before SCT. There was no relationship between plasma VEGF levels and serum CRP levels before SCT, because the serum CRP levels in all patients receiving SCT were negative before transplantation. Therefore, the high plasma VEGF levels before SCT may reflect endothelial injuries of the patients before transplantation. Similarly, it is considered that the high level of VEGF seen in patients with VOD after SCT may be a consequence of endothelial injury caused by conditioning chemoradiotherapy and/or infections. If this is the case the endothelial injury would be a primary cause of VOD, and when the thrombogenic effects [18] [19] [20] of VEGF exceed the endothelium repairing effects of VEGF, VOD may develop in SCT.
The origin of VEGF remains unclear. Since thrombocytopenia was seen in all patients receiving SCT, it is apparent that the total VEGF which we measured is not derived from platelets. However, VEGF may be partially derived from platelets and it may be one of the causes of variation of the peak VEGF levels in the patients. For example, in case 1, whose peak VEGF was high, the onset of VOD synchronized with the platelet recovery. In contrast, in case 4, whose peak VEGF was not so high, the onset of VOD was early and did not synchronize with platelet recovery (Figure 1) . Moreover, the mean platelet count prior to the SCT (15.0 (s.d. 11.0) × 10 4 /l) was significantly lower than in normal controls (52.6 (s.d. 14.8) × 10 4 /l; P Ͻ 0.001), because this study included those patients with aplastic anemia, myelodysplastic syndrome, and Wiskott-Aldrich syndrome, whose platelet counts had not been normal before SCT. Therefore, it was considered that the mean plasma VEGF levels before SCT in our study were lower than normal controls. Similarly, because the platelet counts had not before SCT 89.1 ± 58.7* 22.4 ± 36.4* after SCT 772.1 ± 1213.9** 12.7 ± 42.6** Min. protein C (%, mean ± s.d.)
22.5 ± 5.3** 49.5 ± 17.0** Max. CRP (mg/dl, mean ± s.d.)
16.3 ± 6.5*** 6.9 ± 6.3*** Febrile term (days, mean ± s.d.)
10.2 ± 1.6**** 4.4 ± 4.5**** *P = 0.0012; **P Ͻ 0.001; ***P = 0.0046; ****P = 0.0019. ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; JCML = juvenile chronic myelogenous leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma; RMS = rhabdomyosarcoma; Nbl = neuroblastoma; AA = aplastic anemia; WAS = Wiskot-Aldrich syndrome; GVHD = graft-versus-host disease; CR = complete remission; CP = chronic phase; VEGF = vascular endothelial growth factor. /l), the plasma VEGF levels after SCT were lower than before SCT in non-VOD patients. Thus, platelet counts may have an influence on the plasma VEGF levels. However, the frequency of platelet transfusions in the patients with VOD was 14.8 (s.d. 4.4), and non-VOD was 13.9 (s.d. 6.0) within 30 days after SCT, and there is no significant difference between patients with VOD and without VOD (P = 0.43). Thus, it is considered that the frequency of platelet transfusions is not a major source of VEGF. Since the plasma VEGF levels were significantly high during the short term after SCT in patients with VOD, despite the presence of thrombocytopenia, it suggested that the high VEGF levels after SCT reflected acceleration of VOD. In most cases, the serum VEGF levels gradually decreased during conditioning and then normalized at around day 0, and again elevated in parallel to their hematoBone Marrow Transplantation logical recovery. Since it has been shown that activated human neutrophils secrete VEGF, [21] [22] [23] one of the sources of VEGF in SCT may be granulocytes activated by G-CSF and/or other cytokines. In most patients receiving SCT, the complications such as hemorrhage and VOD happen several days after conditioning chemoradiotherapy, but not immediately after conditioning. These complications mostly coincided with the recovery of granulocyte count, as we have previously demonstrated. 24 In this context, G-CSF administration should be re-evaluated, especially in the cases of patients with high-risk of VOD.
It would be a matter of concern why thrombosis occurs in the hepatic vein after SCT, and extends to VOD. The liver would be easily exposed to bacteria and/or lipopolysaccharide (LPS), which are translocated from the intestinal tract, particularly in patients with severe intestinal mucositis after SCT. We found high LPS levels in patients 8.7 ± 4.9**** 3.7 ± 3.8**** *P Ͻ 0.001; **P = 0.0016; ***P = 0.0057; ****P = 0.001. ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; JCML = juvenile chronic myelogenous leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma; RMS = rhabdomyosarcoma; Nbl = neuroblastoma; AA = aplastic anemia; WAS = Wiskot-Aldrich syndrome; GVHD = graft-versus-host disease; CR = complete remission; CP = chronic phase; VEGF = vascular endothelial growth factor.
receiving SCT (unpublished data). We demonstrated that LPS up-regulates the expression of tissue factor on sinusoidal endothelial cells of the liver. 25, 26 We also previously showed that LPS up-regulates VEGF expression by macrophages in vitro. 27 Furthermore, since drugs such as BU, CY, and CsA are metabolized and/or activated by hepatocytes, the endothelium of sinusoids and hepatic veins are directly exposed to these agents at high concentrations, enough to injure the endothelium. This injury of the endothelium may be the target of the action of VEGF, 28 and may also induce the secretion of VEGF. The acceleration of vasopermeability by VEGF would induce ascites and hemoconcentration with an increase in blood viscosity in the liver. Under this circumstance, if the thrombogenic effects of VEGF operate, thrombosis may develop in the hepatic vein, leading to VOD. A possible involvement of bacterial and/or LPS translocation as an initial trigger for VOD would be supported by the fact that the serum CRP levels and number of febrile episodes were significantly higher in patients with VOD as shown in this study. It is conceivable that bacteria and/or LPS translocation from gut is one of the main etiologies not only for infections and acute GVHD 29 but also for VOD. It has been shown that plasma protein C activities decrease in VOD, [3] [4] [5] and plasma protein C is considered as the clinical parameter for VOD after SCT. Therefore, patients with decreased protein C during SCT are at high risk of VOD. In this study, we found that a plasma protein C activity below 40% after SCT was the critical level for VOD. Furthermore, the serum VEGF levels in patients with protein C below 40% were significantly higher than those in patients with protein C activities above 40%. This indicates that the increase of serum VEGF during SCT is also a potential risk factor for VOD. It remains unclear whether there is a direct relationship between the increase of VEGF and the decrease of protein C. Although several lines of evidence suggest that VEGF up-regulates factor VIII, tissue factor, 30 and thrombomodulin 31 on endothelium in vitro, it remains unclear whether VEGF stimulates protein C production by hepatocytes directly. Nevertheless, it is quite possible that conjunction of both the conditions accelerates venous thrombosis. It will be interesting to investigate whether the elimination or decrease of VEGF by anti-VEGF antibody, soluble VEGF receptor, or VEGF absorption column will provide a novel therapeutic approach for VOD.
In conclusion, although the number of analyses was small, we firstly showed that the serum VEGF levels were significantly higher in patients with VOD. The increase of serum VEGF level synchronized fairly well with the development of VOD after SCT. It is thus conceivable that VEGF is one of the causative cytokines for VOD and may be used as an appropriate clinical parameter of VOD. Moreover, since the serum VEGF levels were significantly higher before SCT in patients with VOD and also in patients with protein C below 40%, monitoring of serum VEGF can be a useful forecasting tool for VOD.
